KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
$1.73
+0 (+0%)
At Close: Apr 26, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
...

Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock Price Crosses Above 50-Day Moving Average of $7.05

 11:18pm, Wednesday, 24'th Nov 2021 Transcript Daily
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)’s share price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $7.05 and traded as high as $7.51. Eiger BioPharmaceuticals shares last traded at $6.79, with a volume of 151,146 shares trading hands. Several equities analysts have recently commented on the […]
...

Eiger Biopharmaceuticals (EIGR) AT HDV KOL Event - Slideshow

 12:56pm, Tuesday, 23'rd Nov 2021 Seeking Alpha

Eiger BioPharmaceuticals' (EIGR) CEO David Cory on Q3 2021 Results - Earnings Call Transcript

 08:11pm, Thursday, 04'th Nov 2021
Eiger BioPharmaceuticals' (EIGR) CEO David Cory on Q3 2021 Results - Earnings Call Transcript

Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates

 07:49pm, Thursday, 04'th Nov 2021
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.07% and 19.65%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences

 04:05pm, Wednesday, 01'st Sep 2021
PALO ALTO, Calif., Sept. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2021 Results - Earnings Call Transcript

 09:37am, Sunday, 08'th Aug 2021
Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2021 Results - Earnings Call Transcript

Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

 04:01pm, Thursday, 05'th Aug 2021
PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism

 08:00am, Thursday, 05'th Aug 2021
PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5

 04:05pm, Thursday, 22'nd Jul 2021
PALO ALTO, Calif., July 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of target

Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

 08:00am, Wednesday, 07'th Jul 2021
PALO ALTO, Calif., July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib)

 08:00am, Tuesday, 29'th Jun 2021
PALO ALTO, Calif. , June 29, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants

 10:53am, Monday, 28'th Jun 2021
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association Scienti

Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session

 08:00am, Monday, 28'th Jun 2021
PALO ALTO, Calif., June 28, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

 04:05pm, Wednesday, 26'th May 2021
PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targete

Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q1 2021 Results - Earnings Call Transcript

 04:30pm, Sunday, 09'th May 2021
Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q1 2021 Results - Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE